Cogent Biosciences Advances Bezuclastinib NDAs; Q1 Net Loss $97.4M
Cogent Biosciences reported its first quarter 2026 financial results and provided significant business updates, highlighting a pivotal year for the company. The FDA accepted its New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis, setting a PDUFA target action date of December 30, 2026, and the company also submitted an NDA for bezuclastinib in GIST under the FDA's Real-Time Oncology Review program. Financially, Cogent ended Q1 2026 with a strong cash position of $866.4 million, projected to fund operations into 2028, despite an increased net loss of $97.4 million for the quarter. The company is preparing for potential dual launches of bezuclastinib in Systemic Mastocytosis and GIST in the second half of 2026.
Key Highlights
- FDA accepted bezuclastinib NDA for NonAdvSM with PDUFA target action date of December 30, 2026.
- Submitted bezuclastinib NDA for GIST under FDA's RTOR program; granted Breakthrough Therapy Designation.
- Ended Q1 2026 with $866.4 million in cash, sufficient to fund operations into 2028.
- Q1 2026 net loss was $97.4 million, compared to $72.0 million in Q1 2025.
- Q1 2026 R&D expenses increased to $75.4 million from $63.0 million YoY.
- Q1 2026 G&A expenses rose to $28.2 million from $11.9 million YoY.
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and GIST in 2H 2026.
Price Impact
More from COGT